Supernus Pharma (SUPN) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Supernus Announces Fourth Quarter and Full Year 2019 Financial Results
February 25, 2020 4:41 PM ESTFourth quarter and full year 2019 total revenue of $100.4 million and $392.8 million, respectively.
Fourth quarter and full year 2019 net product sales of $97.9 million and $383.4 million, respectively.Fourth quarter and full year 2019 operating earnings of $40.8 million and $148.6 million, respectively.FDA assigned PDUFA target action date of November 8, 2020 for review of SPN-812 New Drug Application.Phase III P302 trial of SPN-810 for the treatment of IA in ADHD patients 6 to 11 years old did not meet primary endpoint.
ROCKVILLE, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:... More
